¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Receptor, Angiotensin, Type 1"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • ovulatory type
    ¹è¶õÇü
  • polymyarian type
    ´Ù±ÙÀ°Çü
  • precision type attachment
    Á¤¹ÐÇüºÎÂø
  • propagative type
    Áõ½ÄÇü
  • pyknic body type
    ´Ü½Åºñ¸¸½ÅüÇü
  • parthenogenetic type
    ´Ü¼º»ý½ÄÇü
  • split-electrode-type probe
    ºÐÇÒÀü±Ø´õµëÀÚ
  • sthenic type
    ±Ù·ÂÇü
  • storage-type
    ÃàÀûÇü
  • swaged cast type crown
    ¾ÐÀÎÇü±Ý°ü
  • sympathicotonic type
    ±³°¨½Å°æ±äÀåÇü
  • simple type schizophrenia
    ´Ü¼øÇüÁ¤½ÅºÐ¿­º´
  • viral hepatitis type A
    AÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type B
    BÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type D
    DÇü¹ÙÀÌ·¯½º°£¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • tuberculin-type hypersensitivity
    (¢¡delayed-type hypersensitivity) Áö¿¬°ú¹Î
  • introversion type
    ³»ÇâÇü
  • intuitive type
    Á÷°üÇü
  • lepromatous type
    ³ªº´Á¾Çü
  • leptosomatic type
    ¸¶¸¥Çü
  • mating type
    ±³¹èÇü
  • meromyarian type
    ºÎºÐ±ÙÀ°Çü
  • plaque-type mutation
    ÇöóÅ©Çüµ¹¿¬º¯ÀÌ
  • nomenclatural type
    ºÐ·ùÇÐÀû±âÁظí
  • organic reaction type
    ±âÁú¹ÝÀÀÇü
  • ovulatory type
    ¹è¶õÇü
  • parthenogenetic type
    ´Ü¼º»ý½ÄÇü
  • polymyarian type
    ´Ù±ÙÀ°Çü
  • propagative type
    Áõ½ÄÇü
  • pyknic body type
    ºñ¸¸½ÅüÇü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • acetylcholine receptor
    ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • acetylcholine receptor
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü
  • acetylcholine receptor antibody
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëüÇ×ü
  • acetylcholine receptor antibody assay
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü Ç×Ã¼ÃøÁ¤
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸°¼ö¿ëü.
  • alpha-adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³¯¸°¼ö¿ëü
  • androgen receptor
    ³²¼ºÈ£¸£¸ó ¼ö¿ëü
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen receptor
    Ç׿ø¼ö¿ëü.
  • homing receptor
    ±Í¼Ò¼ö¿ëü
  • immunoglobulin receptor
    ¸é¿ª±Û·ÎºÒ¸° ¼ö¿ëü
  • insulin receptor
    Àν¶¸°¼ö¿ëü(áôé»ô÷).
  • insulin receptor
    Àν¶¸°¼ö¿ëü.
  • platelet receptor
    Ç÷¼ÒÆÇ¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • beta-ARK : beta-adrenergic receptor kinase
    º£Å¸-¾Æµå·¹³¯¸°(¼º)¼ö¿ëü ÀλêÈ­È¿¼Ò.
  • beta-adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸°¼º ¼ö¿ëü
  • cardiac receptor
    ½ÉÀå¼ö¿ëü(ãýíôáôé»ô÷)
  • cell growth,ligand receptor binding
    ¸®°£µå¼ö¿ë±â°áÇÕ (¡­áôé»ÐïÌ¿ùê)
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cholinergic receptor
    Äݸ°(ÀÛµ¿)¼º ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • cold receptor
    ³Ã°¢¼ö¿ëü(Ò²ÊÆáôé»ô÷)(¼ö¿ë±â, °¨¼ö±â)
  • complement receptor
    º¸Ã¼¼ö¿ëü
  • complement receptor 1
    º¸Ã¼ ¼ö¿ëü 1
  • complement receptor 2
    º¸Ã¼¼ö¿ëü 2
  • complement receptor 3
    º¸Ã¼¼ö¿ëü 3
  • complement receptor 4
    º¸Ã¼¼ö¿ëü 4
  • corpuscular receptor
    ¼Òü ¼ö¿ëü
  • distance receptor
    °Å¸®¼ö¿ë±â.
  • distance receptor
    °Å¸®(Ëå×î)¼ö¿ë±â(áôé»Ðï).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • adrenergic receptor
    ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) ¼ö¿ëü(áôé»ô÷)
  • alpha adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³ª¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷)
  • alpha receptor
    ¾ËÆÄ¼ö¿ëü(áôé»ô÷)
  • beta adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸° ¼ö¿ëü(áôé»ô÷)
  • beta receptor
    º£Å¸ ¼ö¿ëü(áôé»ô÷)
  • cyclic AMP receptor protein
    °í¸®AMP ¼ö¿ëü ´Ü¹éÁú(áôé»ô÷Ó±ÛÜòõ)
  • dopamine adrenergic receptor
    "µµÆÄ¹Î ¾Æµå·¹³¯¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷), (ÔÒ) adrenergic receptor"
  • Ehrlich's receptor theory
    ¿¡¸¦¸®È÷ ¼ö¿ëüÀÌ·Ð(áôé»ô÷×âÖå)
  • Fc receptor
    Fc ¼ö¿ëü(áôé»ô÷)
  • floating receptor model
    ºÎÀ¯ ¼ö¿ëü(Ý©ë´áôé»ô÷) ¸ðµ¨
  • glucocorticoid receptor
    ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀÌµå ¼ö¿ëü(áôé»ô÷)
  • H1 receptor
    H1 ¼ö¿ëü(áôé»ô÷)
  • H2 receptor
    H2 ¼ö¿ëü(áôé»ô÷)
  • LDL receptor
    LDL ¼ö¿ëü(áôé»ô÷)
  • ligand-receptor internalization
    ¸®°£µå-¼ö¿ëü(áôé»ô÷) ³»ÀÔ(Ò®ìý)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
BZRP benzodiazepine receptor peripheral [type]
CR1 complement receptor type 1
MCR Medical Corps Reserve; melanocortin receptor; message competition ratio; metabolic clearance rate; m...
PLAUR plasminogen activator receptor, urokinase type
ACE Angiotensin Converting Enzyme
  = Kininase II
  = Dipeptidyl Carboxypepti...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AT(2) Angiotensin type 2
AT1A angiotensin II type 1A
ARB angiotensin receptor blocker
ARB Angiotensin II receptor blocker
AIIRA angiotensin II receptor antagonists
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • receptor activation
    ¼ö¿ëü Ȱ¼ºÈ­, ¼ö¿ë±â Ȱ¼ºÈ­
  • receptor blocking agent
    ¼ö¿ëü Â÷´ÜÁ¦
  • receptor complex
    ¼ö¿ëü º¹ÇÕü, ¼ö¿ë±â º¹ÇÕü
  • receptor destroying enzyme
    ¼ö¿ëü ÆÄ±« È¿¼Ò
    ¼ö¿ëü¸¦ ÆÄ±«ÇÏ¿© ÀûÇ÷±¸ÀÇ ¹ÙÀÌ·¯½º ¿ëÇ÷¿¡ ´ëÇÑ °¨¼ö¼ºÀ» ÀÒ¾î¹ö¸®°Ô ÇÏ´Â È¿¼Ò.
  • receptor potential
    ¼ö¿ë±â ÀüÀ§
    ÀÏÁ¤ÇÑ ¹°¸®È­ÇÐÀû Àڱؿ¡ ´ëÇÏ¿© ½Å°æ ´ÜÀ§ ¼ö¿ëü¿¡¼­ ¹ß»ýÇÏ´Â Å»ºÐ±Ø.
  • receptor site
    ¼ö¿ëü ºÎÀ§, ¼ö¿ëºÎ
    ƯÁ¤ÇÑ »ý¹°ÇÐÀû ¹ÝÀÀÀ» ÃÊ·¡ÇÏ´Â ºÐÀÚ °áÇÕÀÌ ÀϾ´Â ƯÁ¤ ºÎÀ§.
  • receptor theory
    ¼ö¿ë±â ÀÌ·Ð
    Ç×ü »ý¼º ¼¼Æ÷ÀÇ Ç¥¸é¿¡´Â ƯÁ¤ Ç×ü¿¡ »óÀÀÇÏ´Â Ç׿øÀÌ °áÇÕÇ϶ó ¼ö¿ëü°¡ Á¸ÀçÇÏ¸ç ±× ¼ö¿ëüÀÇ ±¸Á¶´Â Ç×üÀÇ ±¸Á¶¿Í °°´Ù´Â ÀÌ·Ð.
  • specific membrane receptor
    ƯÁ¤ ¸· ¼ö¿ë±â
  • specific opiate receptor site
    Ưº°ÇÑ ¾ÆÆí ¼ö¿ëºÎ
  • specific receptor
    ƯÀÌ ¼ö¿ëü, ƯÀÌ ¼ö¿ë±â
  • stretch receptor
    ½ÅÀå ¼ö¿ë±â
  • tactile receptor
    Ã˰¢ ¼ö¿ë±â
    Ã˰¢À» ¼ö¿ëÇÒ ¼ö ÀÖ°Ô ¸Å°³ÇØÁÖ´Â Á¶Á÷.
  • tension receptor
    Àå·Â ¼ö¿ë±â
  • Vasopressor receptor
    Ç÷°ü ¼öÃà ¼ö¿ëü
  • visceral receptor
    ³»Àå ¼ö¿ë±â
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
gene rearrangement, delta-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the delta-chain of antigen receptors.
(12 Dec 1998)
gene rearrangement, gamma-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the gamma-chain of antigen receptors.
(12 Dec 1998)
genes, T-cell receptor DNA sequences, in cells of the t-lymphocyte lineage, that code for T-cell receptors. The tcr genes are formed by somatic rearrangement (see gene rearrangement, t-lymphocyte and its children) of germline gene segments, and resemble ig genes in their mechanisms of diversity generation and expression.
(12 Dec 1998)
genes, T-cell receptor alpha DNA sequences encoding the alpha chain of the T-cell receptor. The genomic organization of the tcr alpha genes is essentially the same in all species and is similar to the organization of ig genes.
(12 Dec 1998)
genes, T-cell receptor beta DNA sequences encoding the beta chain of the T-cell receptor. The genomic organization of the tcr beta genes is essentially the same in all species and is similar to the organization of ig genes.
(12 Dec 1998)
genes, T-cell receptor delta DNA sequences encoding the delta chain of the T-cell receptor. The delta-chain locus is located entirely within the alpha-chain locus.
(12 Dec 1998)
genes, T-cell receptor gamma DNA sequences encoding the gamma chain of the T-cell receptor. The human gamma-chain locus is organised similarly to the tcr beta-chain locus.
(12 Dec 1998)
receptor 1. A molecular structure within a cell or on the surface characterised by selective binding of a specific substance and a specific physiologic effect that accompanies the binding, for example, cell surface receptors for peptide hormones, neurotransmitters, antigens, complement fragments and immunoglobulins and cytoplasmic receptors for steroid hormones.
2. A sensory nerve terminal that responds to stimuli of various kinds.
(18 Nov 1997)
receptor aggregation Chemically stimulated aggregation of cell surface receptors, which potentiates the action of the effector cell.
(12 Dec 1998)
receptor agonist A substance that mimics a specificneurotransmitter, is able to attach to that neurotransmitter's receptor and thereby produces the same action that theneurotransmitter usually produces. Drugs are often designed as receptor agonists to treat a variety of diseases and disorders whenthe original chemical substance is missing or depleted.
(22 May 1997)
receptor-CD3 complex, antigen, T-cell Molecule composed of the non-covalent association of the T-cell antigen receptor (receptors, antigen, T-cell) with the CD3 complex (antigens, CD3). This association is required for the surface expression and function of both components. The molecule consists of up to seven chains: either the alpha/beta or gamma/delta chains of the T-cell receptor, and four or five chains in the CD3 complex.
(12 Dec 1998)
receptor, chemokine A molecule that receives a chemokine and acts as a dock for a chemokine. Several chemokine receptors are essential co-receptors for HIV.
(12 Dec 1998)
receptor downregulation A phenomenon observed in many cells: following stimulation with a ligand the number of receptors for that ligand on the cell surface diminishes because internalisation exceeds replenishment. Often used very loosely, thus destroying the utility of the term.
(18 Nov 1997)
receptor mediated endocytosis Endocytosis of molecules by means of a specific receptor protein that normally resides in a coated pit, but may enter this structure after complex formation occurs. The structure then forms a coated vesicle that delivers its contents to the endosome whence it may enter the cytoplasm or the lysosomal compartment. Many bacterial toxins and viruses enter cells by this route.
(18 Nov 1997)
receptor potential The transmembrane potential difference of a sensory cell. Such cells are not generally excitable, but their response to stimulation is a gradual change in their resting potential.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á